Generation Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference
11 Abril 2023 - 8:30AM
Generation Bio Co. (Nasdaq:GBIO), a biotechnology company
innovating genetic medicines for people living with rare and
prevalent diseases, announced that Geoff McDonough, M.D., president
and chief executive officer, will participate in a fireside chat at
the 22nd Annual Needham Virtual Healthcare on Tuesday, April 18th
at 3:00 p.m. EST.
A live webcast of the panel will be available on
the investor section of the company’s website at
investors.generationbio.com. A replay will be available there for
30 days following the event.
About Generation Bio
Generation Bio is innovating genetic medicines to
provide durable, redosable treatments for people living with rare
and prevalent diseases. The company’s non-viral genetic medicine
platform incorporates a novel DNA construct called closed-ended
DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery
system, or ctLNP; and a highly scalable capsid-free manufacturing
process that uses proprietary cell-free rapid enzymatic synthesis,
or RES, to produce ceDNA. This approach is designed to enable
multi-year durability from a single dose, to deliver large genetic
payloads, including multiple genes, to specific tissues and cell
types, and to allow titration and redosing to adjust or extend
expression levels in each patient. RES has the potential to expand
Generation Bio’s manufacturing scale to hundreds of millions of
doses to support its mission to extend the reach of genetic
medicine to more people, living with more diseases, around the
world.
For more information, please visit
www.generationbio.com.
Investors and Media
Contact Maren Killackey Generation
Bio mkillackey@generationbio.com 857-371-4638
Generation Bio (NASDAQ:GBIO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Generation Bio (NASDAQ:GBIO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024